RBC Capital Reiterates Outperform on ADC Therapeutics, Maintains $8 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Gregory Renza has reiterated an Outperform rating on ADC Therapeutics (NYSE:ADCT) and maintained a price target of $8.
March 14, 2024 | 3:12 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital maintains an Outperform rating and a $8 price target on ADC Therapeutics.
The reiteration of an Outperform rating and the maintenance of a $8 price target by a reputable analyst like Gregory Renza from RBC Capital could instill confidence among investors and potentially lead to a positive short term impact on ADC Therapeutics' stock price. Analyst ratings and price targets are significant indicators for investors, and a positive outlook from a well-regarded financial institution can influence market perception and investor sentiment towards the stock.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100